



GeoVax Labs, Inc. is a clinical-stage biotechnology company developing multi-antigen infectious disease vaccines and solid tumor immunotherapies using novel proprietary platforms.

### Mission Driven

Addressing infectious diseases, solid tumor cancers and biosecurity priorities.

### High-Value Pipeline

Pipeline evaluating targets focused on solid tumor cancers, Mpox/smallpox, COVID-19 and other infectious diseases.

### Biosecurity Alignment

Strengthening U.S. biodefense & global health security; reducing foreign dependency.

### Media Contact:

**Jessica Starman**  
media@geovax.com

### Partnership Contact:

**John Sharkey, PhD**  
VP, Business Development  
jsharkey@geovax.com



www.geovax.com

# Advancing Multi-Antigen Vaccines & Solid Tumor Cancer Therapies

**Near term clinical development milestones in Mpox/smallpox, COVID-19, and Head & Neck Cancer**

## Investment Highlights



- **Experienced Team:** Proven track record in delivering significant shareholder value (Leadership Team)
- **Catalyst-Rich Pipeline:** Multiple Phase 2 readouts and trial initiations planned through 2026
- **Strong IP Estate:** Over 130 patents across 22 different families
- **Large Unmet Needs:** 40M immunocompromised Americans underserved by current COVID-19 vaccines; strong global need and demand for expanded Mpox/smallpox vaccine supply

## Lead Clinical Programs



- **GEO-MVA:** Mpox/smallpox vaccine with **expedited clinical pathway positioned for commercialization and revenue generation.**
- **Gedeptin®:** Tumor agnostic cancer immunotherapy with FDA Orphan Drug designation preparing for Phase 2 trial in 1<sup>st</sup> line head & neck cancer
- **GEO-CM04S1:** COVID-19 vaccine in two ongoing Phase 2 trials, comparing against mRNA vaccine among immunocompromised patients

## Upcoming Milestones



- **1H26:** Phase 2; CLL patient results reported and peer-review publication
- **1H26:** Phase 2; cell transplant patient results reported
- **2H26:** GEO-MVA Mpox/smallpox clinical trial initiation – expedited pathway to commercialization
- **2H26:** Phase 2; Gedeptin + Immune Checkpoint Inhibitor initiation
- **2H26:** AGE1 continuous cell-line manufacturing – Demonstrate scalable, continuous production process supporting GEO-MVA commercial readiness and U.S.-based supply resilience

## Market Potential Addressing Unmet Medical Needs



# Advancing a Novel Pipeline in High-Value Areas

| Product  | Initial Target     | Development Stage                 |
|----------|--------------------|-----------------------------------|
| GEO-MVA  | Mpox/Smallpox      | Pivotal Phase 3 initiating H2 '26 |
| CM04S1   | COVID-19           | Phase 2                           |
| Gedepin® | Head & Neck Cancer | Phase 2 initiating H2 '26         |


## Modified Vaccinia Ankara (MVA) Platform

**MVA is a viral vector vaccine platform** that uses a safe/harmless virus as a delivery vehicle delivering instructions into cells to trigger immunity to fight pathogens (viruses). MVA features include:



- **Exceptionally Safe:** does not replicate in humans
- **Special Populations:** proven to be safe including among patients with weakened immune systems (40M in U.S.; ~400M worldwide), pregnant women and children
- **Provides Durable (Long Lasting) & Broad Immunity:** induces both antibodies and T-cell immunity, potentially providing longer effectiveness including against new viral variants
- **Multi-Antigenic:** can address multiple diseases in same vaccine
- **Thermal Stability:** doesn't require ultra-cold storage

## Gedepin® “Tumor Agnostic” Technology



- **Tumor-Selective Activation only in gene-expressing tumor cells**
- **Platform-Agnostic Application across multiple solid tumors**
- **Human Clinical Phase1/2 evidence of tumor-killing activity**
- **Combination optionality with Immune Checkpoint Inhibitors**

**Tumor-selective gene therapy evaluated in solid tumors, with potential applicability across indications and in combination regimens**